A Compassionate Use Study of Leronlimab in Breast Cancer
NCT04313075 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-07-15
Summary
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
Conditions
- Metastatic Triple-Negative Breast Carcinoma
Interventions
- DRUG
-
Leronlimab
Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Sponsors & Collaborators
-
CytoDyn, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Chemotherapy in Treating Patients With Breast Cancer
NCT00012129 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
NCT01702571 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
NCT01650506 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
NCT01300962 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
NCT02435680 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
NCT01068704 ·Status: COMPLETED ·Phase: PHASE2
-
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT04563507 ·Status: RECRUITING ·Phase: PHASE2
-
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
NCT01067989 ·Status: TERMINATED ·Phase: PHASE2
-
Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab
NCT01730677 ·Status: UNKNOWN ·Phase: PHASE2
-
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
NCT00191373 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
NCT00073528 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
NCT00080197 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
NCT03109080 ·Status: COMPLETED ·Phase: PHASE1
-
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
NCT00031278 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
NCT00470704 ·Status: COMPLETED ·Phase: PHASE2
-
Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
NCT00424164 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
NCT04690855 ·Status: TERMINATED ·Phase: PHASE2
-
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
NCT01105312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
NCT00193076 ·Status: COMPLETED ·Phase: PHASE2
-
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
NCT01467310 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
NCT01451580 ·Status: UNKNOWN ·Phase: PHASE2
-
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
NCT01273610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
NCT06156761 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
NCT02681562 ·Status: UNKNOWN ·Phase: PHASE2
-
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
NCT00316875 ·Status: COMPLETED ·Phase: PHASE1